Received GSK royalties of $60.3 million, net product revenues of $11.5 million and license revenue of $8.0 million in the first quarter of 2023Repurchased $40.3 million of common stock and paid off $96.2 million of 2023 convertible notesBURLINGAME, Calif. (BUSINESS WIRE) Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” o.
Received GSK royalties of $60.3 million, net product revenues of $11.5 million and license revenue of $8.0 million in the first quarter of 2023
Repurchased $40.3 million of common stock and paid. | May 9, 2023